Skip to content
Disclosery

Indaba Capital Management, L.P.

Follow

13F filer, CIK 1524362, SAN FRANCISCO, CA

Indaba Capital Management, L.P. reported $207,547,740 across 10 holdings for the quarter ended 2024-12-31, in a 13F-HR filed 2025-02-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001011438-25-000175

Period
2024-12-31
Reported value
$208M
Holdings
10
Top 10 weight
100%
New
4
Sold out
3

Largest buys vs the previous quarter

SecurityShares changeApprox. value
Blue Owl Capital Corp IIInew+2,793,366$40.3M
EQCadded+4,850,000$8.58M
ESPRnew+3,000,000$6.6M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

None.

Holdings, Q4 2024

Share positions as resolved from 13F-HR 0001011438-25-000175, largest first. % of portfolio is the value over $207,547,740, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
Blue Owl Capital Corp IIIBlue Owl Capital Corp IIIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 2,793,366 shares 2,793,366$40.3M19.41%new
ONTFON24 INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,240,256 shares; 2024Q4: 4,240,256 shares 4,240,256$27.4M13.2%0Timeline
EQCEQUITY COMMONWEALTHQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,700,000 shares; 2024Q4: 9,550,000 shares 9,550,000$16.9M8.14%+4,850,000Timeline
ESPRESPERION THERAPEUTICS INC NEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 3,000,000 shares 3,000,000$6.6M3.18%newTimeline

Principal amounts

Notes and convertibles filed as a face amount (PRN). A face amount is never added to a share count (H6).

SecurityTypeAmountValueChange
BANDWIDTH INCBANDWIDTH INC NOTE 0.500% 4/0principal40,250,000$32.2M0
REVANCE THERAPEUTICS INCREVANCE THERAPEUTICS INC BONDprincipal25,000,000$24Mnew
SUMMIT HOTEL PPTYSSUMMIT HOTEL PPTYS NOTE 1.500% 2/1principal22,664,000$22M+18,164,000
IRONWOOD PHARMACEUTICALS INCIRONWOOD PHARMACEUTICALS INC NOTE 1.500% 6/1principal14,000,000$13M+5,000,000
TRAVERE THERAPEUTICS INCTRAVERE THERAPEUTICS INC NOTE 2.500% 9/1principal13,000,000$12.8Mnew
ACCELERATE DIAGNOSTICS INCACCELERATE DIAGNOSTICS INC NOTE 5.000%12/1principal24,685,998$12.3M+602,097

Sold out in Q4 2024

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
Esperion Therapeutics IncEsperion Therapeutics Inc33,750,000$32Mprincipal
XOMETRY INCXOMETRY INC21,750,000$18.6Mprincipal
STANDARD BIOTOOLS INCSTANDARD BIOTOOLS INC7,660,000$7.63Mprincipal

How Q4 2024 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001011438-25-000175 base2025-02-14acceptance time not in the bulk data set